Press Release Details

RESEARCH TRIANGLE PARK, N.C., May 26, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:              

• The Jefferies 2016 Healthcare Conference in New York on Thursday, June 9, 2016 at 8:00 a.m. Eastern Time
   
• The JMP Securities Life Sciences Conference in New York on Tuesday, June 21, 2016 at 10:00 a.m. Eastern Time

Links to a live audio webcast and replay of these presentations may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst's ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema, avoralstat, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

CONTACT:

Robert Bennett,

BioCryst Pharmaceuticals,

+1-919-859-7910

Source: Biocryst Pharmaceuticals

News Provided by Acquire Media